Iambic Therapeutics, Inc. IAM
14.84 USD -0.54 (-3.54%)
At closeNov 13, 2026, 4:01 AM EST
14.81 -0.03 -0.20%
Pre-market · Nov 13, 4:01 AM ET
14.02 Day range 15.39
9.60 52-week range 25.00
- YTD
- -21.52%
- 1 year
- -21.52%
News
benzinga.com Jefferies Initiates Coverage On Iambic Therapeutics with Buy Rating, Announces Price Target of $35 Jefferies analyst Akash Tewari initiates coverage on Iambic Therapeutics (NASDAQ:IAM) with a Buy rating and announces Price Target of $35.
benzinga.com Iambic Therapeutics Jumps 17% After-Hours as Wall Street Turns Bullish on Its AI-Powered Drug Discovery Platform Iambic Therapeutics shares surge as BofA and Jefferies initiate coverage with Buy ratings and bullish price targets.
benzinga.com Crude Oil Falls Over 3%; NRG Energy Shares Jump After Strong Q3 Results U.S. stocks surged Monday, led by a 2.1% S&P 500 gain; NRG jumped on strong results, while Zura Bio plunged 75% after trial failures.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Edesa Biotech (NASDAQ:EDSA) stock moved upwards by 39.0% to $2.98 during Monday's regular session. The market value of their outstanding shares is at $20.6 million. Heron Therapeutics…
benzinga.com CNH Industrial, Planet Labs, Ferguson Enterprises And Other Big Stocks Moving Higher On Monday U.S. stocks rallied Monday; CNH surged 13.5% after strong Q3 results and raised guidance, while several stocks posted double-digit gains.
benzinga.com This Supernus Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Analysts initiated bullish coverage on IAM, AMRO, CWH, SUPN, issuing Buy, Outperform or Overweight ratings with price targets.
benzinga.com JP Morgan Initiates Coverage On Iambic Therapeutics with Overweight Rating, Announces Price Target of $22 JP Morgan initiates coverage on Iambic Therapeutics (NASDAQ:IAM) with a Overweight rating and announces Price Target of $22.
benzinga.com Citigroup Initiates Coverage On Iambic Therapeutics with Buy Rating, Announces Price Target of $22 Citigroup analyst Geoff Meacham initiates coverage on Iambic Therapeutics (NASDAQ:IAM) with a Buy rating and announces Price Target of $22.
globenewswire.com Iambic to participate in Jefferies Global Healthcare Conference Co-Founder and CEO Tom Miller joins AI drug discovery panel on November 18, 2026 Co-Founder and CEO Tom Miller joins AI drug discovery panel on November 18, 2026
benzinga.com B of A Securities Initiates Coverage On Iambic Therapeutics with Buy Rating, Announces Price Target of $30 B of A Securities analyst Alec Stranahan initiates coverage on Iambic Therapeutics (NASDAQ:IAM) with a Buy rating and announces Price Target of $30.- benzinga.com Iambic Therapeutics Presents Updated Clinical Results From Its IAM1363 Inhibitor At ESMO Congress 2026 Iambic Therapeutics, Inc. (Iambic) (Nasdaq: IAM), a clinical-stage life sciences and technology company developing novel medicines using its AI-driven platform, today announced updated clinical data…